Next Article in Journal
The Roles of YAP/TAZ and the Hippo Pathway in Healthy and Diseased Skin
Next Article in Special Issue
Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors
Previous Article in Journal
Cisplatin-Induced Ototoxicity in Rats Is Driven by RIP3-Dependent Necroptosis
Previous Article in Special Issue
Systematic Review of the Current Status of Human Sarcoma Cell Lines
 
Search for Articles:
Title / Keyword
Author / Affiliation
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
Journals
Cells
Volume 8
Issue 5
10.3390/cells8050410
cells-logo
Submit to this Journal Review for this Journal Edit a Special Issue
► Article Menu

Article Menu

share announcement thumb_up
...
textsms
...
Open AccessReview

Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review

by
Kei Kawaguchi
1,2,3,
Qinghong Han
1,
Shukuan Li
1,
Yuying Tan
1,
Kentaro Igarashi
1,
Takashi Murakami
1,
Michiaki Unno
3 and
Robert M. Hoffman
1,2,*
1
AntiCancer, Inc., San Diego, CA 92111, USA
2
Department of Surgery, University of California, San Diego, CA 92093, USA
3
Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 9808575, Japan
*
Author to whom correspondence should be addressed.
Cells 2019, 8(5), 410; https://doi.org/10.3390/cells8050410
Received: 2 April 2019 / Revised: 13 April 2019 / Accepted: 17 April 2019 / Published: 2 May 2019
(This article belongs to the Special Issue Patient-Derived Cancer Models from Basic Study to Clinical Application)
View Full-Text Download PDF
Browse Figures

Abstract

An excessive requirement for methionine (MET), termed MET dependence, appears to be a general metabolic defect in cancer and has been shown to be a very effective therapeutic target. MET restriction (MR) has inhibited the growth of all major cancer types by selectively arresting cancer cells in the late-S/G2 phase, when they also become highly sensitive to cytotoxic agents. Recombinant methioninase (rMETase) has been developed to effect MR. The present review describes the efficacy of rMETase on patient-derived orthotopic xenograft (PDOX) models of recalcitrant cancer, including the surprising result that rMETase administrated orally can be highly effective. View Full-Text
Keywords: recombinant methioninase; methionine dependence; nude mice; orthotopic implantation; patient-derived tumor recombinant methioninase; methionine dependence; nude mice; orthotopic implantation; patient-derived tumor
►▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
SciFeed

Share and Cite

MDPI and ACS Style

Kawaguchi, K.; Han, Q.; Li, S.; Tan, Y.; Igarashi, K.; Murakami, T.; Unno, M.; Hoffman, R.M. Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review. Cells 2019, 8, 410. https://doi.org/10.3390/cells8050410

AMA Style

Kawaguchi K, Han Q, Li S, Tan Y, Igarashi K, Murakami T, Unno M, Hoffman RM. Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review. Cells. 2019; 8(5):410. https://doi.org/10.3390/cells8050410

Chicago/Turabian Style

Kawaguchi, Kei; Han, Qinghong; Li, Shukuan; Tan, Yuying; Igarashi, Kentaro; Murakami, Takashi; Unno, Michiaki; Hoffman, Robert M. 2019. "Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review" Cells 8, no. 5: 410. https://doi.org/10.3390/cells8050410

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop